Myeloproliferative Disorders: Clinical Trials

2,240 trials for Myeloproliferative Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1206 completed, 316 terminated, 235 recruiting, 184 unknown. 1021 Phase 2, 616 Phase 1, 233 Phase 3, 158 Not applicable, 45 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 21021Completed 571, Terminated 162, Recruiting 88, Active not recruiting 69, Unknown 64, Withdrawn 45, Not yet recruiting 20, Suspended 2
Phase 1616Completed 349, Terminated 104, Recruiting 64, Active not recruiting 39, Withdrawn 34, Unknown 19, Not yet recruiting 5, Suspended 2
Phase 3233Completed 134, Terminated 30, Unknown 26, Active not recruiting 19, Recruiting 15, Not yet recruiting 6, Withdrawn 2, Suspended 1
Not applicable158Completed 78, Terminated 26, Recruiting 24, Unknown 14, Not yet recruiting 9, Withdrawn 5, Active not recruiting 2
Phase 445Completed 24, Unknown 9, Terminated 6, Not yet recruiting 2, Withdrawn 2, Active not recruiting 1, Recruiting 1
Early Phase 116Completed 7, Recruiting 4, Unknown 3, Terminated 1, Withdrawn 1

Follow Myeloproliferative Disorders: new trials by email Literature Review of Myeloproliferative Disorders trials Research Report on Myeloproliferative Disorders

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Rusfertide in Adults With Polycythemia Vera in China
Rusfertide - Polycythemia Vera
Phase 2Not yet recruitingTakeda242027-03-012026-08-28
Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT
imetelstat - High-risk Myeloid Malignancy, Allogenic Stem Cell Transplantation
Phase 1Not yet recruitingUniversity of Wisconsin, Madison272027-02-012026-11-02
A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait
Leukemia, Myeloid, Chronic-Phase
Not yet recruitingNovartis Pharmaceuticals4002027-01-312026-11-10
Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Phase 2Not yet recruitingJonsson Comprehensive Cancer Center352027-01-302026-11-05
WELL-MPN: A Digital Lifestyle App for Patients With MPNs
WELL-MPN Digital App - Myeloproliferative Neoplasms (MPNs)
Not applicableNot yet recruitingBrigham and Women's Hospital752027-01-012026-09-29
Asciminib Frontline Risk Adapted
Dasatinib 80mg QD (5 days per week), Standarc of Care - Chronic Myeloid Leukemia (CML)
Phase 2Not yet recruitingProf. Dr. med. Andreas Hochhaus2002027-01-012026-09-04
Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms
Oral THU-decitabine - Myelofibrosis, MPN - Accelerated or Blast Phase
Phase 2Not yet recruitingJohn Mascarenhas202027-01-012026-10-14
Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome
Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia
Phase 2Not yet recruitingFred Hutchinson Cancer Center522027-01-012026-09-14
A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs
ELVN-001, TKI - Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Phase 3Not yet recruitingEnliven Therapeutics4502026-12-312026-10-29
Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies
Ossium HPC, Marrow, Standard of care living donor - Haplo Related, Standard of care living donor - Mismatched Unrelated - Hematologic Malignancy, Acute Leukemia
Not applicableNot yet recruitingOssium Health, Inc.3002026-12-012026-09-10
A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant
Maintenance Therapy, No intervention - Myeloid Disorders, Myelodysplastic Syndromes
Phase 2Not yet recruitingMedical College of Wisconsin4502026-12-012026-10-13
Revumenib in Patients With Myelofibrosis
Revumenib, Ruxolitinib, FEDRATINIB - Myelofibrosis, Post-polycythemia Vera Myelofibrosis
Phase 1 / Phase 2Not yet recruitingJohn Mascarenhas322026-12-012026-07-29
A Study to Better Understand the Diagnosis and Treatment of Polycythaemia Vera
No Intervention - Polycythemia Vera
Not yet recruitingTakeda902026-12-012026-10-09
Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms
Pacritinib, Venetoclax, Azacitidine - Myeloproliferative Neoplasm
Phase 1Not yet recruitingRoswell Park Cancer Institute202026-12-012026-10-21
A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
HS-10382, Imatinib, Dasatinib - Chronic Myeloid Leukemia
Phase 3Not yet recruitingJiangsu Hansoh Pharmaceutical Co., Ltd.4082026-12-012026-10-21
A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region
Chronic Myeloid Leukemia
Not yet recruitingNovartis Pharmaceuticals802026-12-012026-11-10
Study of LusPACercept in Participants With Myelofibrosis Associated Anemia and Thrombocytopenia
Luspatercept, Pacritinib - Myelofibrosis
Phase 2Not yet recruitingCase Comprehensive Cancer Center502026-12-012026-11-13
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
pacritinib - Myelodysplastic Syndromes
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)1602026-11-192026-11-16
Jaktinib in Ruxolitinib-Treatment Failure Myelofibrosis: A Multicenter, Prospective, Real-World Observational Study
Jaktinib - Myeloproliferative Neoplasms/Myelofibrosis
Not yet recruitingAffiliated Hospital of Nantong University802026-11-102026-11-09
A Multicenter, Prospective, Observational Study of Jaktinib in Newly Diagnosed Myelofibrosis
Jaktinib - Myeloproliferative Neoplasms/Myelofibrosis
Not yet recruitingAffiliated Hospital of Nantong University802026-11-102026-11-09

Showing 20 of 2240. Sign in to see all of them.

Narrower conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (878)  ·  Leukemia, Myeloid, Acute (822)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (649)  ·  Primary Myelofibrosis (624)  ·  Myelodysplastic Syndromes (623)  ·  Leukemia (618)  ·  Leukemia, Myeloid, Chronic-Phase (439)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (411)  ·  Lymphoma, Non-Hodgkin (385)  ·  Multiple Myeloma (358)  ·  Hodgkin Disease (357)  ·  Blast Crisis (356)  ·  Congenital Abnormalities (327)  ·  Leukemia, Myeloid, Accelerated Phase (318)

Broader conditions

Hemic and Lymphatic Diseases (2239)  ·  Bone Marrow Diseases (2207)  ·  Hematologic Diseases (2183)  ·  Neoplasms (1777)  ·  Neoplasms by Histologic Type (1668)  ·  Leukemia, Myeloid (1568)  ·  Pathological Conditions, Signs and Symptoms (1454)  ·  Pathologic Processes (1442)  ·  Disease Attributes (1426)  ·  Chronic Disease (1418)  ·  Leukemia (1034)  ·  Immune System Diseases (820)  ·  Immunoproliferative Disorders (785)  ·  Lymphatic Diseases (779)

Interventions

Cyclophosphamide (227)  ·  fludarabine phosphate (197)  ·  Imatinib Mesylate (172)  ·  Cytarabine (155)  ·  Busulfan (151)  ·  Peripheral Blood Stem Cell Transplantation (150)  ·  ruxolitinib (137)  ·  Mycophenolic Acid (134)  ·  Whole-Body Irradiation (127)  ·  Tacrolimus (125)  ·  Cyclosporine (110)  ·  fludarabine (110)  ·  Filgrastim (109)  ·  nilotinib (107)  ·  Methotrexate (93)

Sponsors

M.D. Anderson Cancer Center (128)  ·  Novartis Pharmaceuticals (120)  ·  National Cancer Institute (NCI) (112)  ·  Fred Hutchinson Cancer Center (103)  ·  Memorial Sloan Kettering Cancer Center (44)  ·  Bristol-Myers Squibb (38)  ·  Masonic Cancer Center, University of Minnesota (37)  ·  City of Hope Medical Center (35)  ·  Incyte Corporation (34)  ·  Case Comprehensive Cancer Center (30)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (30)  ·  Gruppo Italiano Malattie EMatologiche dell'Adulto (27)  ·  National Heart, Lung, and Blood Institute (NHLBI) (27)  ·  Roswell Park Cancer Institute (26)  ·  H. Lee Moffitt Cancer Center and Research Institute (18)

Countries

United States (1440)  ·  Italy (271)  ·  France (269)  ·  Germany (220)  ·  Canada (189)  ·  United Kingdom (167)  ·  Spain (146)  ·  Australia (121)  ·  China (117)  ·  South Korea (114)  ·  Belgium (107)  ·  Poland (92)  ·  Netherlands (91)  ·  Israel (86)  ·  Austria (79)

Top investigators

Jorge Cortes, MD (19)  ·  John Mascarenhas, MD (16)  ·  Brenda Sandmaier (15)  ·  Ronald Hoffman, MD (12)  ·  Jorge E Cortes, MD (8)  ·  B. Douglas Smith, MD (7)  ·  Judith Karp (7)  ·  Michele Baccarani, MD (7)

Results publications

PMID 32499241, PMID 24383844, PMID 25527568, PMID 35235189, PMID 23524640, PMID 23620574, PMID 28835440, PMID 30885996, PMID 23065508, PMID 25361995, PMID 31375516, PMID 35982483, PMID 36184192, PMID 37042865, PMID 39516087, PMID 20965785, PMID 22825216, PMID 34699069, PMID 37553873, PMID 40535755, PMID 41758981, PMID 41958363, PMID 42316774, PMID 16775234, PMID 17151364, PMID 17715389, PMID 18997171, PMID 19797518, PMID 21403127, PMID 21447834, PMID 21450900, PMID 21715313, PMID 22133778, PMID 22430088, PMID 22692507, PMID 23116602, PMID 23515925, PMID 23704092, PMID 23911705, PMID 24323036, PMID 24859364, PMID 24919837, PMID 26069290, PMID 26888022, PMID 27291777, PMID 28273028, PMID 28543980, PMID 28572163, PMID 28962635, PMID 29217781

NIH funding

P30CA015704 (43), P30CA006973 (30), P30CA033572 (22), P30CA043703 (20), 2023 (19), P01CA018029 (18), U01CA070095 (17), U10CA032102 (17), P01CA108671 (16), P30CA016672 (16), U10CA031946 (15), 2018 (12), P30CA072720 (11), 2017 (10), P30CA015083 (10)